Clinical trial
Irinotecan in Treating Patients With Advanced Solid Tumors
NCT00004051 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004051 |
|---|---|
| Title | Irinotecan in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Study to Evaluate Orally Administered Irinotecan HCL (CPT-11) Given as a Powder-Filled Capsule Formulation Daily for 14 Days Every Three Weeks in Patients With Advanced Solid Tumors |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 40 |
| Start date | Aug 1, 1998 |
| Primary completion | Jul 1, 2001 |
| Completion | Dec 1, 2009 |
| First posted | May 20, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: